Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,391,230 papers from all fields of science
Search
Sign In
Create Free Account
Teriparatide Acetate
Known as:
Parathyroid Hormone (1-34) Acetate
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Narrower (1)
Forteo
Teriparatide
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Safety Profiles, Pharmacokinetics, and Changes in Bone Turnover Markers After Twice‐Weekly Subcutaneous Administration of Teriparatide in Healthy Japanese Postmenopausal Women: A Single‐Blind…
Y. Kumagai
,
A. Ose
,
Kosuke Tanaka
,
T. Sugimoto
Clinical pharmacology in drug development
2019
Corpus ID: 85564046
Once‐weekly injection of 56.5‐μg teriparatide formulation is a potent therapeutic agent for osteoporosis treatment. However, this…
Expand
2019
2019
Application of parathyroid hormone combined with low frequency pulse electromagnetic field in elderly patients with intertrochanteric fracture
Tienan Qu
,
D. Guo
,
Jinxian Pan
2019
Corpus ID: 219826800
Objective To investigate the effect of parathyroid hormone (PTH) mimicker teriparatide acetate combined with low frequency pulse…
Expand
2018
2018
Successful treatment of MRONJ in the palatal torus with teriparatide
K. Mizohata
,
T. Sano
,
K. Oishi
,
S. Morita
Journal of Oral and Maxillofacial Surgery…
2018
Corpus ID: 81062288
2017
2017
Population Pharmacokinetic and Exposure–Response Analysis of Weekly Teriparatide in Osteoporosis Patients
A. Ose
,
M. Serada
,
K. Yamashita
,
K. Tsurui
,
Y. Tanigawara
Journal of clinical pharmacology
2017
Corpus ID: 20269919
Teriparatide is a potent therapeutic agent for the treatment of osteoporosis. One of the aims of this analysis was to develop a…
Expand
Review
2015
Review
2015
[On "2015 Guidelines for Prevention and Treatment of Osteoporosis". Medical treatment for osteoporosis].
M. Yamauchi
,
T. Sugimoto
Clinical calcium
2015
Corpus ID: 31484066
The main revisions to the item of medical treatment in the 2015 edition of the Guidelines for Prevention and Treatment of…
Expand
2014
2014
Pharmacokinetics of teriparatide after subcutaneous administration to volunteers with renal failure: a pilot study.
Hiromitsu Imai
,
Makoto Watanabe
,
T. Fujita
,
Hiroshi Watanabe
,
K. Harada
,
T. Moritoyo
International journal of clinical pharmacology…
2014
Corpus ID: 9689476
BACKGROUND AND OBJECTIVE Teriparatide acetate was developed in the form of a synthetic analogue of the Nterminal peptide (1-34…
Expand
2012
2012
The role of the liver and kidneys in the pharmacokinetics of subcutaneously administered teriparatide acetate in rats
M. Serada
,
Aki Sakurai-Tanikawa
,
+4 authors
Terutomo Kohira
Xenobiotica; the fate of foreign compounds in…
2012
Corpus ID: 25670579
Teriparatide acetate, a synthetic polypeptide fragment consisting of human parathyroid hormone residues 1-34 [hPTH(1-34)], is a…
Expand
1999
1999
Teriparatide. LY 333334, MN 10T, parathyroid hormone (1-34), parathyroid hormone (1-34)-Asahi, parathyroid hormone (1-34)-Eli Lilly, parathyroid hormone (1-34)-Rhône-Poulenc Rorer, teriparatide…
Drugs in R&D
1999
Corpus ID: 41472376
1993
1993
[The usefulness of the teriparatide acetate (Parathar) infusion test in the diagnosis of pseudohypoparathyroidism].
F. Rius
,
I. Salinas
,
J. Reverter
,
E. Pizarro
,
A. Lucas
Medicina clínica (Ed. impresa)
1993
Corpus ID: 45211003
In pseudohypoparathyroidism there is a resistance to the action of the parathormone in its target organs. Patients with this…
Expand
Review
1988
Review
1988
Synthetic human parathyroid hormone 1-34 fragment for diagnostic testing.
L. E. Mallette
Annals of Internal Medicine
1988
Corpus ID: 38149309
Since bovine parathyroid extract became unavailable for stimulatory testing, the differentiation between hypoparathyroidism and…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE